Defibrotide, a polydeoxyribonucleotide of mammalian origin, has been shown to reduce the blood level of the plasminogen activator inhibitor, and so to increase the activity of tissue plasminogen activator without any adverse effect. A randomized, double-blind, placebo-controlled study has been done in 22 patients, 14 with peripheral vascular disease, 6 with coronary heart disease and 2 with cerebrovascular disease. Patients were given defibrotide 400 mg b.d. or identical placebo for 30 days and the parameters of fibrinolysis were evaluated before and after the treatment. A significant increase in tissue plasminogen activator activity at rest and after venostasis was observed after defibrotide; tissue plasminogen activator antigen at rest and after venostasis was not affected by either treatment. Defibrotide significantly reduced plasminogen activator inhibitor activity and antigen at rest. Only one patient complained of gastric pain after placebo treatment. The study shows that defibrotide has profibrinolytic property and that it could be used to explore the role of plasminogen activator inhibitor in venous and arterial thrombosis.

EFFECT OF ORAL DEFIBROTIDE ON TISSUE-PLASMINOGEN ACTIVATOR AND TISSUE-PLASMINOGEN ACTIVATOR INHIBITOR BALANCE / Violi, Francesco; Ferro, Domenico; M., Saliola; C., Quintarelli; Basili, Stefania; F., Balsano. - In: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. - ISSN 0031-6970. - STAMPA. - 42:4(1992), pp. 379-383.

EFFECT OF ORAL DEFIBROTIDE ON TISSUE-PLASMINOGEN ACTIVATOR AND TISSUE-PLASMINOGEN ACTIVATOR INHIBITOR BALANCE

VIOLI, Francesco;FERRO, Domenico;BASILI, Stefania;SALIOLA, Mirella
1992

Abstract

Defibrotide, a polydeoxyribonucleotide of mammalian origin, has been shown to reduce the blood level of the plasminogen activator inhibitor, and so to increase the activity of tissue plasminogen activator without any adverse effect. A randomized, double-blind, placebo-controlled study has been done in 22 patients, 14 with peripheral vascular disease, 6 with coronary heart disease and 2 with cerebrovascular disease. Patients were given defibrotide 400 mg b.d. or identical placebo for 30 days and the parameters of fibrinolysis were evaluated before and after the treatment. A significant increase in tissue plasminogen activator activity at rest and after venostasis was observed after defibrotide; tissue plasminogen activator antigen at rest and after venostasis was not affected by either treatment. Defibrotide significantly reduced plasminogen activator inhibitor activity and antigen at rest. Only one patient complained of gastric pain after placebo treatment. The study shows that defibrotide has profibrinolytic property and that it could be used to explore the role of plasminogen activator inhibitor in venous and arterial thrombosis.
atherosclerosis; defibrotide; fibrinolysis; tissue plasminogen activator t-pa; plasminogen activator inhibitor pai-1; inhibitor pai 1; plasminogen activator
01 Pubblicazione su rivista::01a Articolo in rivista
EFFECT OF ORAL DEFIBROTIDE ON TISSUE-PLASMINOGEN ACTIVATOR AND TISSUE-PLASMINOGEN ACTIVATOR INHIBITOR BALANCE / Violi, Francesco; Ferro, Domenico; M., Saliola; C., Quintarelli; Basili, Stefania; F., Balsano. - In: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. - ISSN 0031-6970. - STAMPA. - 42:4(1992), pp. 379-383.
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/112863
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 13
social impact